Long-Term Survival Benefits of Intensive Chemo-Immunotherapy with Autologous Transplant in Mantle Cell Lymphoma

Overview

In a retrospective cohort of 199 mantle cell lymphoma (MCL) patients treated with intensive rituximab and cytarabine-based high-dose sequential chemotherapy (R-HDS) and autologous stem cell transplantation (ASCT), a 7-year overall survival (OS) of 67% and progression-free survival (PFS) of 53.2% were observed. The study highlights durable remissions and potential cure in a subset of patients, with prognostic factors such as MIPI score, age, LDH levels, and histology significantly influencing outcomes.

Background

Mantle cell lymphoma is a rare and aggressive B-cell lymphoma with historically poor median survival of 3–5 years. Intensive first-line chemo-immunotherapy combined with autologous stem cell transplantation has improved outcomes but long-term survival and cure potential remain uncertain. Prognostic tools like the MCL international prognostic index (MIPI) help stratify risk but do not fully predict clinical course. This study analyzed long-term outcomes and late complications in a large Italian cohort treated with the R-HDS protocol and autograft.

Data Highlights

Key Findings

• At a median follow-up of 7 years, 60% of patients were alive, with 48% undergoing two ASCTs and 85% achieving complete or unconfirmed complete remission.
• Patients with low-risk MIPI scores had significantly better OS, PFS, and DFS compared to intermediate-high and high-risk groups.
• Multivariable analysis identified intermediate-high/high MIPI score, older age, elevated LDH, bulky disease, and blastoid histology as predictors of worse survival and progression outcomes.
• No significant survival difference was observed between patients receiving one versus two ASCTs.
• Patients with blastoid histology had poorer outcomes, with a 13-year OS of 37.5% compared to typical histology.
• Proliferative index (Ki-67) did not significantly impact long-term outcomes in this intensive treatment setting.

Clinical Implications

Intensive first-line chemo-immunotherapy with R-HDS followed by autologous transplantation offers durable long-term survival and potential cure in MCL, especially in patients with favorable prognostic profiles. Risk stratification using MIPI remains critical for guiding prognosis and management. The lack of survival benefit from a second ASCT suggests that one transplant may suffice in many cases, potentially reducing treatment-related toxicity.

Conclusion

This large retrospective study demonstrates that intensive chemo-immunotherapy combined with autologous transplantation yields substantial long-term survival benefits in mantle cell lymphoma, with a significant proportion of patients achieving prolonged remission and potential cure. Prognostic factors continue to influence outcomes despite intensive treatment.

References

1. Rossi et al. 2020 -- Intensive First-Line Chemo-Immunotherapy with Autologous Transplantation in 199 Patients with Mantle Cell Lymphoma